Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

NCT01605318 | Terminated Phase 1 FDA Drug

• 1 other identifier: IMMU-130-02
• Study Type: interventional
• Target: 92
• Locations: 1 country
• Sites: 7

Brief Summary

The goal of this clinical study is to determine the dosing and safety of labetuzumab govitecan (formerly known as IMMU-130; hMN-14-SN38, antibody-drug conjugate) in participants with colorectal cancer.

Conditions

Metastatic Colorectal Cancer; Colon Cancer; Rectal Cancer

Keywords

Previously treated Metastatic colorectal cancer; Previously treated Colon cancer; Previously treated Rectal cancer

Outcome Measures

Primary Outcomes (2)

• Percentage of Participants With Adverse Events and Serious Adverse Events (SAEs)

  From first dose date up to approximately 2 years after the last dose or until disease progression

• Percentage of Participants With Laboratory Abnormalities

  From first dose date up to approximately 2 years after the last dose or until disease progression

Secondary Outcomes (6)

• Duration of Response

  From first documentation of PR or CR to the earlier of the first documentation of PD or death from any cause (Up to approximately 2 years after the last dose or until disease progression)

• Progression-free Survival

  From first dose date up to 12 weeks post treatment (Up to approximately 2 years after the last dose or until disease progression)

• Time to Progression

  From first dose of study treatment up to PD (Up to approximately 2 years after the last dose or until disease progression)

• Overall Survival

  From first dose date up to approximately 2 years

• Time-to-treatment Failure

  From first dose date up to 8 treatment cycles (each cycle = 21 days) (Up to approximately 24 weeks)

Study Arms (3)

Phase1: Dose-escalation Phase: Labetuzumab Govitecan (LG) Once Weekly Dosing

EXPERIMENTAL

Participants will receive 8, 12 and 16 mg/dose of LG once weekly dosing until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to up to 8 cycles, with a contingency to examine intermediate dose levels of 10 or 14 mg/kg, or if necessary to a lower dose level of 6 mg/kg.

Drug: Labetuzumab Govitecan (LG)

Phase1: Dose-escalation Phase: LG Twice Weekly Dosing

EXPERIMENTAL

Participants will receive 6 and 9 mg/kg per dose twice weekly dose of LG until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to up to 8 cycles. A lower dose level of 4 mg/kg may be added if \> 1 out of 3 or 2 out of 6 participants are unable to tolerate all 4 doses without dose delay or reduction.

Drug: Labetuzumab Govitecan (LG)

Phase 2: Dose-expansion Phase: LG Once or Twice Weekly Dosing

EXPERIMENTAL

Participants will receive selected doses of LG once or twice weekly until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to 8 cycles.

Drug: Labetuzumab Govitecan (LG)

Interventions

Labetuzumab Govitecan (LG) DRUG

Administered as a slow intravenous (IV) infusion.

Also known as: hMN14-SN38, Labetuzumab-SN38, Antibody-Drug Conjugate, IMMU-0130, GS-0130

Phase 2: Dose-expansion Phase: LG Once or Twice Weekly Dosing; Phase1: Dose-escalation Phase: LG Twice Weekly Dosing; Phase1: Dose-escalation Phase: Labetuzumab Govitecan (LG) Once Weekly Dosing

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically confirmed colorectal adenocarcinoma.
• Stage IV (metastatic) disease.
• Previously treated with at least one prior irinotecan-containing regimen for colorectal cancer.
• Adequate performance status (Eastern Cooperative Oncology Group (ECOG) 0 or 1).
• Expected survival \> 6 months.
• Carcinoembryonic antigen (CEA) plasma levels \> 5 ng/mL.
• Measurable disease by computed tomography (CT) or Magnetic resonance imaging (MRI).
• At least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities.
• At least 2 weeks beyond corticosteroids.
• Adequate hematology without ongoing transfusional support (hemoglobin \> 9 g/dL, absolute neutrophil count (ANC) \> 1,500 per mm\^3, platelets \> 100,000 per mm\^3).
• Adequate renal and hepatic function (creatinine ≤ 1.5 x IULN, bilirubin ≤ institutional upper limit of normal (IULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).
• Otherwise, all toxicity at study entry ≤ Grade 1 by National cancer institute common terminology criteria for adverse events (NCI CTC) v4.0.

You may not qualify if:

• Women who are pregnant or lactating.
• Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period.
• Individuals with Gilbert's disease or known central nervous system (CNS) metastatic disease.
• Individuals with CEA plasma levels \> 1000 ng/mL must be approved in advance by the Sponsor.
• Presence of bulky disease (defined as any single mass \> 10 cm in its greatest dimension).
• Individuals with active ≥ grade 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction.
• Individuals with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while individuals with other prior malignancies must have had at least a 3-year disease-free interval.
• Individuals known to be human immunodeficiency virus (HIV) positive, hepatitis B positive, or hepatitis C positive.
• Known history of unstable angina, myocardial infarction, or congestive heart failure present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy.
• Known history of clinically significant active chronic obstructive pulmonary disease (COPD), or other moderate-to-severe chronic respiratory illness present within 6 months.
• Infection requiring intravenous antibiotic use within 1 week.
• Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

Sponsors & Collaborators

• Gilead Sciences: lead

Study Sites (7)

UCLA Jonsson Comprehensive Cancer Center

Santa Monica, California, 90404, United States

Location

University of Colorado Anschutz Medical Campus

Aurora, Colorado, 80045, United States

Location

Helen F. Graham Cancer Center-Christiana Care

Newark, Delaware, 19713, United States

Location

IUHealth Goshen Center for Cancer Care

Goshen, Indiana, 46526, United States

Location

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43202, United States

Location

Fox Chase

Philadelphia, Pennsylvania, 19111, United States

Location

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37212, United States

Location

Related Publications (5)

• Govindan SV, Goldenberg DM. New antibody conjugates in cancer therapy. ScientificWorldJournal. 2010 Oct 12;10:2070-89. doi: 10.1100/tsw.2010.191.

  PMID: 20953556 BACKGROUND

• Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009 Oct 1;15(19):6052-61. doi: 10.1158/1078-0432.CCR-09-0586. Epub 2009 Sep 29.

  PMID: 19789330 BACKGROUND

• Moon SJ, Govindan SV, Cardillo TM, D'Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008 Nov 13;51(21):6916-26. doi: 10.1021/jm800719t. Epub 2008 Oct 22.

  PMID: 18939816 BACKGROUND

• Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol Cancer Res Treat. 2005 Aug;4(4):375-91. doi: 10.1177/153303460500400406.

  PMID: 16029057 BACKGROUND

• Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. doi: 10.1200/JCO.2017.73.9011. Epub 2017 Aug 17.

  PMID: 28817371 BACKGROUND

MeSH Terms

Conditions

Colorectal Neoplasms; Colonic Neoplasms; Rectal Neoplasms

Interventions

labetuzumab govitecan; Immunoconjugates

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Antibodies; Immunoglobulins; Serum Globulins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Globulins; Immunologic Factors; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses

Study Officials

• Gilead Study Director

  Gilead Sciences

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 22, 2012
• First Posted: May 24, 2012
• Study Start: February 12, 2013
• Primary Completion: January 3, 2017
• Study Completion: January 3, 2017
• Last Updated: January 24, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (7)